OAKTREE ACQUISITION CORP I-A

OACCNASDAQ

🏆 #3000 by market capUS Equity

$10.74▲ $0.00 (+0.00%)

🌅 Pre-market$10.74▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 0.0%

7d▲ 0.4%

14d▲ 0.4%

30d▲ 0.5%

1y▲ 2.8%

🏦Market Cap

$264M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Fair

Trading Snapshot

Day Range: $10.66 – $10.95
52-Week Range: $10.30 – $10.88
Volume: $4.00B
Avg Volume: $3.61B
Shares Outstanding: 24.6M
Next Earnings: Oct 19, 2026

Fundamentals Snapshot

Annual Revenue: $50M
Last Q Revenue: $14M
P/E Ratio: —
P/S Ratio: —
EPS (TTM): —
Dividend Yield: —

Why Investors Own OACC

✓High-growth profile — revenue up +3.5% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 8% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$50M▲ +8.4% YoY

Gross Margin (TTM)

78.3%▲ +2.2% YoY

Operating Income (TTM)

$19M▲ +8.4% YoY

Free Cash Flow (TTM)

$4M▲ +8.4% YoY

About OAKTREE ACQUISITION CORP I-A

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.

🦦